Author: Paul Armentano, NORML Deputy Director

The Feds Finally Recognize The Anti-Cancer Potential Of Cannabis — 36 Years Too Late!

Scientific trials have for decades documented the anti-cancer properties of cannabis and its constituents. Yet it took until this week for the website of the National Institute of Cancer, a component of the U.S. government’s National Institutes of Health, to finally acknowledged the herb’s therapeutic utility for patients living with disease or suffering from the […]

The Feds Finally Recognize The Anti-Cancer Potential Of Cannabis — 36 Years Too Late!

Scientific trials have for decades documented the anti-cancer properties of cannabis and its constituents. Yet it took until this week for the website of the National Institute of Cancer, a component of the U.S. government’s National Institutes of Health, to finally acknowledged the herb’s therapeutic utility for patients living with disease or suffering from the […]

Cannabis Inhalation Associated With Spontaneous Tumor Regression, Study Says

[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To have NORML’s media advisories and legislative updates delivered straight to your in-box, sign up for ‘NORML News’ here. To read more about the anticancer properties of cannabinoids, please see NORML’s literature review here.]
Cannabis inhalation is associated with spontaneous brain tumor […]

NORML’s Weekly Legislative Round Up

Marijuana law reform legislation is pending in over twenty states, and liberalization measures have been pre-filed in many more. Below is this week’s edition of NORML’s Weekly Legislative Round Up — activists’ one-stop guide to the latest statewide votes and happenings relevant to marijuana law reform.
For a listing of all of the pending marijuana law […]

DEA Enacts Federal Ban On ‘Marijuana-Like’ Herbal Products Sold Over The Counter

The United States Drug Enforcement Administration (DEA) today, as anticipated, exercised its ‘emergency scheduling authority’ to criminally prohibit the possession and sale of chemical agents contained in so-called ‘fake’ herbal marijuana products, commonly sold over the counter under the brand names ‘K2’ and ‘Spice.’ The agency had initially announced its intent to outlaw the chemicals […]

“Legitimate Debate?” Not If The Drug Czar Has His Way

Several weeks ago, President Obama stated that he believed the subject of drug legalization and regulation was “an entirely legitimate topic for debate.” Yet recent actions by White House Office of National Drug Control Policy head Gil Kerlikowske imply that this administration has no interest in having this debate in the public arena — at […]

NORML’s Weekly Legislative Round Up

Marijuana law reform legislation is pending in over twenty states, and progressive measures have been pre-filed in many more. Below is this week’s edition of NORML’s Weekly Legislative Round Up — activists’ one-stop guide to pending marijuana law reform legislation around the country.
** A note to first time readers: NORML can not introduce legislation in […]

The DEA Is Ready For Pharmaceutical Pot — Are You?

Recently on the NORML blog and in NORML’s weekly media release we informed you of the U.S. Drug Enforcement Administrations’ intentions to reclassify plant-derived THC from a schedule I to schedule III controlled substance under the federal Controlled Substances Act.
Today on the website Alternet.org I write about the forces motivating this proposed change and […]

NORML’s Weekly Legislative Round Up

Marijuana law reform legislation is pending in over twenty states, and progressive measures have been pre-filed in many more. Below is this week’s edition of NORML’s Weekly Legislative Round Up — activists’ one-stop guide to pending marijuana law reform legislation around the country.
** A note to first time readers: NORML can not introduce legislation in […]